Related references
Note: Only part of the references are listed.Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Neo approaches to cancer vaccines
Lelia Delamarre et al.
SCIENCE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer
Hua Li Wang et al.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS (2014)
Targeting the Tumor Microenvironment with Interferon-β Bridges Innate and Adaptive Immune Responses
Xuanming Yang et al.
CANCER CELL (2014)
Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors
Juan Fu et al.
CANCER RESEARCH (2014)
Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8+ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Ruey-Shyang Soong et al.
CLINICAL CANCER RESEARCH (2014)
Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Madhav V. Dhodapkar et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
A novel method for synthetic vaccine construction based on protein assembly
Zhida Liu et al.
SCIENTIFIC REPORTS (2014)
Dendritic cell-targeted vaccines - hope or hype?
Wolfgang Kastenmueller et al.
NATURE REVIEWS IMMUNOLOGY (2014)
PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer
Cecile Badoual et al.
CANCER RESEARCH (2013)
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Omid Hamid et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2013)
Dendritic-Cell-Based Therapeutic Cancer Vaccines
Karolina Palucka et al.
IMMUNITY (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sortase-mediated modification of αDEC205 affords optimization of antigen presentation and immunization against a set of viral epitopes
Lee Kim Swee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Type I interferon response and innate immune sensing of cancer
Mercedes B. Fuertes et al.
TRENDS IN IMMUNOLOGY (2013)
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
Mikayel Mkrtichyan et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2013)
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Suzanne L. Topalian et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
PD-1/PD-L1 Blockade Can Enhance HIV-1 Gag-specific T Cell Immunity Elicited by Dendritic Cell-Directed Lentiviral Vaccines
Bingbing Dai et al.
MOLECULAR THERAPY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Control of Cervicovaginal HPV-16 E7-Expressing Tumors by the Combination of Therapeutic HPV Vaccination and Vascular Disrupting Agents
Qi Zeng et al.
HUMAN GENE THERAPY (2011)
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells
Mercedes B. Fuertes et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Mark S. Diamond et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates
Barbara J. Flynn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients
Sytse J. Piersma
CANCER MICROENVIRONMENT (2011)
Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody
Cheolho Cheong et al.
BLOOD (2010)
Route of Antigen Uptake Differentially Impacts Presentation by Dendritic Cells and Activated Monocytes
Alice O. Kamphorst et al.
JOURNAL OF IMMUNOLOGY (2010)
Human papillomavirus oncoproteins: pathways to transformation
Cary A. Moody et al.
NATURE REVIEWS CANCER (2010)
Host immune responses to cervical cancer
Swati Patel et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2009)
Inhibition of Melanoma Growth by Targeting of Antigen to Dendritic Cells via an Anti-DEC-205 Single-Chain Fragment Variable Molecule
Theron S. Johnson et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic human papillomavirus vaccines: current clinical trials and future directions
Chien-Fu Hung et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells
Godwin Nchinda et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: A phase I escalating-dose trial
Alessandro D. Santin et al.
JOURNAL OF VIROLOGY (2008)
Human papillomavirus infection: Epidemiology and pathophysiology
Marc Steben et al.
GYNECOLOGIC ONCOLOGY (2007)
Advances in dendritic cell-based therapeutic vaccines for cervical cancer
Stefania Bellone et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system
Pedro Berraondo et al.
CANCER RESEARCH (2007)
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
AD Santin et al.
GYNECOLOGIC ONCOLOGY (2006)
Migration of dendritic cell based cancer vaccines:: in vivo veritas?
GJ Adema et al.
CURRENT OPINION IN IMMUNOLOGY (2005)
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
LC Bonifaz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
New tools for antigen delivery to the MHC class I pathway
G Morón et al.
TRENDS IN IMMUNOLOGY (2004)
Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7
DA Sewell et al.
CANCER RESEARCH (2004)
Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation:: relevance for the immune modulatory effect in multiple sclerosis
B Schreiner et al.
JOURNAL OF NEUROIMMUNOLOGY (2004)
Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance
L Bonifaz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the αMβ2 integrin (CD11b/CD18)
P Guermonprez et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
A PEST-like sequence in listeriolysin O essential for Listeria monocytogenes pathogenicity
AL Decatur et al.
SCIENCE (2000)
Share Paper
